VKH
ALBO

Virtu KCG Holdings’s Albireo Pharma Inc ALBO Stock Holding History

Virtu KCG Holdings’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-967
Closed -$91K – 4372
2013
Q3 		$91K Buy
+967
New +$126K ﹤0.01% 3394

Other funds holding ALBO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Virtu KCG Holdings's ALBO Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Albireo Pharma Inc (ALBO) in Q4 2016, closing a stake of 408 shares — an estimated $5K sold.

Virtu KCG Holdings first reported a position in ALBO in Q1 2015 and held it in 7 quarters. The position peaked at $29K in Q1 2015. 19 funds tracked by Wall St. Rank hold ALBO as of Q4 2016.

  • Virtu KCG Holdings reported no remaining Albireo Pharma Inc position as of Q4 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 408 Albireo Pharma Inc shares in Q4 2016, an estimated $5K.
  • Virtu KCG Holdings first reported a position in Albireo Pharma Inc in Q1 2015 and held it in 7 quarters.
  • Virtu KCG Holdings's Albireo Pharma Inc position peaked at $29K in Q1 2015.
  • 19 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.